[HTML][HTML] Association between a 22-feature genomic classifier and biopsy Gleason upgrade during active surveillance for prostate cancer
BH Press, T Jones, O Olawoyin, SD Lokeshwar… - European Urology Open …, 2022 - Elsevier
Abstract Background Although the Decipher genomic classifier has been validated as a
prognostic tool for several prostate cancer endpoints, little is known about its role in …
prognostic tool for several prostate cancer endpoints, little is known about its role in …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
BH Press, T Jones, O Olawoyin… - European …, 2022 - eu-openscience.europeanurology …
Abstract Background Although the Decipher genomic classifier has been validated as a
prognostic tool for several prostate cancer endpoints, little is known about its role in …
prognostic tool for several prostate cancer endpoints, little is known about its role in …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
BH Press, T Jones, O Olawoyin, SD Lokeshwar… - medRxiv, 2021 - medrxiv.org
Abstract Background Although the Decipher genomic classifier has been validated as a
prognostic tool for several prostate cancer endpoints, little is known about its role in …
prognostic tool for several prostate cancer endpoints, little is known about its role in …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer.
BH Press, T Jones, O Olawoyin… - European Urology …, 2022 - europepmc.org
Background Although the Decipher genomic classifier has been validated as a prognostic
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer.
BH Press, T Jones, O Olawoyin, SD Lokeshwar… - 2022 - escholarship.org
BackgroundAlthough the Decipher genomic classifier has been validated as a prognostic
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
[HTML][HTML] Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
BH Press, T Jones, O Olawoyin… - European Urology …, 2022 - ncbi.nlm.nih.gov
Abstract Background: Although the Decipher genomic classifier has been validated as a
prognostic tool for several prostate cancer endpoints, little is known about its role in …
prognostic tool for several prostate cancer endpoints, little is known about its role in …
[PDF][PDF] Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
PC Sprenkle - scholar.archive.org
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During
Active Surveillance for Prostate Cancer Page 1 1 Association Between a 22-feature Genomic …
Active Surveillance for Prostate Cancer Page 1 1 Association Between a 22-feature Genomic …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
BH Press, T Jones, O Olawoyin… - European Urology …, 2022 - scholars.northwestern.edu
Background: Although the Decipher genomic classifier has been validated as a prognostic
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
BH Press, T Jones, O Olawoyin… - European urology …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Although the Decipher genomic classifier has been validated as a prognostic
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
tool for several prostate cancer endpoints, little is known about its role in assessing the risk …
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
BH Press, T Jones, O Olawoyin, SD Lokeshwar… - 2021 - europepmc.org
Background: Although the Decipher genomic classifier has been validated as a prognostic
tool for several prostate cancer endpoints, little is known about its role in assessing risks of …
tool for several prostate cancer endpoints, little is known about its role in assessing risks of …